Brokerages Set Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Target Price at $18.88

Posted by George Bondi on Jun 3rd, 2026

Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Get Free Report) has received an average rating of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $20.1429.

Several equities research analysts recently weighed in on LXEO shares. Chardan Capital reiterated a “buy” rating and issued a $17.00 target price on shares of Lexeo Therapeutics in a research note on Monday, May 11th. Weiss Ratings lowered shares of Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. Finally, Wall Street Zen raised shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th.

Get Our Latest Stock Analysis on Lexeo Therapeutics

Lexeo Therapeutics Stock Performance

NASDAQ LXEO opened at $4.51 on Wednesday. The firm has a 50-day simple moving average of $5.74 and a 200 day simple moving average of $7.36. Lexeo Therapeutics has a twelve month low of $2.72 and a twelve month high of $10.99. The stock has a market cap of $354.13 million, a PE ratio of -3.11 and a beta of 1.38.

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.04. Research analysts forecast that Lexeo Therapeutics will post -1.23 earnings per share for the current fiscal year.

Insider Transactions at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 55,000 shares of the stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $5.69, for a total value of $312,950.00. Following the completion of the transaction, the chief executive officer owned 340,106 shares of the company’s stock, valued at $1,935,203.14. This represents a 13.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 59,644 shares of company stock valued at $336,462 over the last three months. Corporate insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. 683 Capital Management LLC raised its position in Lexeo Therapeutics by 21.4% in the fourth quarter. 683 Capital Management LLC now owns 1,120,000 shares of the company’s stock worth $11,122,000 after purchasing an additional 197,338 shares in the last quarter. Spruce Street Capital LP acquired a new position in Lexeo Therapeutics in the fourth quarter worth about $1,738,000. ProShare Advisors LLC acquired a new position in Lexeo Therapeutics in the fourth quarter worth about $146,000. Allworth Financial LP raised its position in Lexeo Therapeutics by 1,002.9% in the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock worth $34,000 after purchasing an additional 3,079 shares in the last quarter. Finally, UBS Group AG raised its position in Lexeo Therapeutics by 12.5% in the fourth quarter. UBS Group AG now owns 281,083 shares of the company’s stock worth $2,791,000 after purchasing an additional 31,174 shares in the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

About Lexeo Therapeutics

(Get Free Report)

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.